Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 6/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | UBE2M | P61081 | 1/20 | 0.30 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653647 | 1.00 | CCR1 (0.57) | CCR1CHRM2CCR5HRH1ADRA1D | |
| SCHEMBL653646 | 1.00 | CCR1 (0.57) | CCR1CHRM2CCR5HRH1ADRA1D | |
| SCHEMBL655057 | 0.96 | CCR1 (0.58) | CCR1CHRM2CCR5HRH1ADRA1D | |
| SCHEMBL655056 | 0.96 | CCR1 (0.58) | CCR1CHRM2CCR5HRH1ADRA1D | |
| SCHEMBL15478323 | 0.94 | CCR1 (0.56) | CCR1CHRM2CCR5HRH1ADRA1D | |
| SCHEMBL653068 | 0.94 | CCR1 (0.56) | CCR1CHRM2CCR5HRH1ADRA1D | |
| SCHEMBL656075 | 0.94 | CCR1 (0.56) | CCR1CHRM2CCR5HRH1ADRA1D | |
| SCHEMBL14579823 | 0.93 | CCR1 (0.59) | CCR1CHRM2CCR5HRH1ADRA1D | |
| SCHEMBL652856 | 0.93 | CCR1 (0.59) | CCR1CHRM2CCR5HRH1ADRA1D | |
| SCHEMBL10287629 | 0.93 | CCR1 (0.59) | CCR1CHRM2CCR5HRH1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | CCR1 10/4885CHRM2 1772/4885CCR5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.